|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers |
Description of Invention:
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause some T-cells to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target cells for destruction. This is a promising new therapeutic approach known as adoptive cell therapy.
CD22 is a cell surface protein that is expressed on a large number of B-cell lineage hematological cancers. Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins. This technology concerns the use of a high affinity antibody binding fragment to CD22 as the targeting moiety of a CAR, adding adoptive cell therapy as a new prospective treatment for certain leukemias and lymphomas.
Applications:
- Treatment of diseases associated with increased or preferential expression of CD22
- Specific diseases include hematological cancers such as chronic lymphocytic leukemia, hairy cell leukemia and pediatric acute lymphoblastic leukemia
Advantages:
- Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients
- Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream
- Expression of CD22 only on mature cells allows the avoidance of stem cell elimination during treatment
- High affinity of the antibody binding fragment for CD22 increases the likelihood of successful targeting
Development Status:
- Pre-clinical
- In vitro data available
- In vivo data available (animal)
Inventors:
Ira H Pastan (NCI)
Rimas J Orentas (NCI)
Crystal L Mackall (NCI)
Patent Status:
HHS, Reference No. E-265-2011/0
US, Application No. 61/549,516 filed 20 Oct 2011
PCT, Application No. PCT/US2012/061025 filed 19 Oct 2012
Related Technologies:
US, Patent No. 7,355,012, Issued 08 Apr 2008, Reference No. E-129-2001/0
US, Application No. 60/325,360 filed 26 Sep 2001, Reference No. E-129-2001/0
US, Patent No. 7,777,019, Issued 17 Aug 2010, Reference No. E-129-2001/0
US, Application No. 13/438,725 filed 03 Apr 2012, Reference No. E-129-2001/0
Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Chimeric Antigen Receptor for CD22, High Affinity. A gene vector to target T cells to B cell leukemia and lymphoma. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov. Click here to view the NCI collaborative opportunity announcement.
For Licensing Information Please Contact:
David Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: lambertsond@mail.nih.gov
Phone: 301-435-4632
Fax: 301-402-0220
Ref No: 2360
Updated: 02/2012
|
|
|
|
| |
|
|
|
|